Impact of hepatitis C virus infection on clinical outcome in recipients after allogeneic hematopoietic cell transplantation

American Journal of Hematology

Volumn 88, Issue 6, 2013, Pages 477-484

  Nakasone, Hideki ^a,b,c   Kurosawa, Saiko ^c,d   Yakushijin, Kimikazu ^c,e   Taniguchi, Shuichi ^c,f   Murata, Makoto ^g   Ikegame, Kazuhiro ^h   Kobayashi, Takeshi ⁱ   Eto, Tetsuya ^j   Miyamura, Koichi ^k   Sakamaki, Hisashi ⁱ   Morishima, Yasuo ^l   Nagamura, Tokiko ^m   Suzuki, Ritsuro ⁿ   Fukuda, Takahiro ^c,d  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Working Group for HSCT Complications of the Japan Society for Hematopoietic Cell Transplantation   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f TORANOMON HOSPITAL   (Japan)

^g NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h HYOGO COLLEGE OF MEDICINE   (Japan)

ⁱ TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^j HAMANOMACHI HOSPITAL   (Japan)

^k JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^l AICHI CANCER CENTER HOSPITAL   (Japan)

^m UNIVERSITY OF TOKYO   (Japan)

ⁿ NAGOYA UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; FEMALE; GRAFT FAILURE; HEPATITIS C; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPHIL; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GRAFT SURVIVAL; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878166348     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23436     Document Type: Article

References (41)

1. Powles R. 50 years of allogeneic bone-marrow transplantation. Lancet Oncol 2010;11:305-306.
2. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-362.
3. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-567.
4. World Health Organization. Media Centre. Hepatitis C. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed July 9, 2012.
5. Ministry of Health Labour and Welfare. Information Examination Medical Treatment Enlightenment. About hepatitis. Available from: http://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou09/hepatitis_about.html. Accessed July 9, 2012.
6. Sharara AI, Hunt CM, Hamilton JD. Hepatitis C. Ann Intern Med 1996;125:658-668.
7. Peffault de Latour R, Ribaud P, Robin M, et al. Allogeneic hematopoietic cell transplant in HCV-infected patients. J Hepatol 2008;48:1008-1017.
8. Locasciulli A, Testa M, Valsecchi MG, et al. The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: A prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group. Transplantation 1999;68:1486-1491.
9. Ljungman P, Johansson N, Aschan J, et al. Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients. Blood 1995;86:1614-1618.
10. Tomás JF, Pinilla I, García-Buey ML, et al. Long-term liver dysfunction after allogeneic bone marrow transplantation: Clinical features and course in 61 patients. Bone Marrow Transplant 2000;26:649-655.
11. Strasser SI, Myerson D, Spurgeon CL, et al. Hepatitis C virus infection and bone marrow transplantation: A cohort study with 10-year follow-up. Hepatology 1999;29:1893-1899.
12. Socié G, de Latour RP, McDonald GB. Hepatitis C virus and allogeneic stem cell transplantation still matters! Haematologica 2009;94:170-172.
13. Peffault de Latour R, Lévy V, Asselah T, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 2004;103:1618-1624.
14. Ramos CA, Saliba RM, de Pádua L, et al. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica 2009;94:249-257.
15. Ivantes CA, Amarante H, Ioshii SO, et al. Hepatitis C virus in long-term bone marrow transplant survivors. Bone Marrow Transplant 2004;33:1181-1185.
16. Atsuta Y, Suzuki R, Yoshimi A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol 2007;86:269-274.
17. Gratwohl A. The EBMT risk score. Bone Marrow Transplant 2012;47:749-756.
18. Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009;15:367-369.
19. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825-828.
20. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-217.
21. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993;118:255-267.
22. Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987;44:778-783.
23. Maruta A, Kanamori H, Fukawa H, et al. Liver function tests of recipients with hepatitis C virus infection after bone marrow transplantation. Bone Marrow Transplant 1994;13:417-422.
24. Hogan WJ, Maris M, Storer B, et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: A study of 193 patients. Blood 2004;103:78-84.
25. García-Monzón C, Sánchez-Madrid F, García-Buey L, et al. Vascular adhesion molecule expression in viral chronic hepatitis: evidence of neoangiogenesis in portal tracts. Gastroenterology 1995;108:231-241.
26. Kurkijärvi R, Yegutkin GG, Gunson BK, et al. Circulating soluble vascular adhesion protein 1 accounts for the increased serum monoamine oxidase activity in chronic liver disease. Gastroenterology 2000;119:1096-1103.
27. Henry SD, Metselaar HJ, Van Dijck J, et al. Impact of steroids on hepatitis C virus replication in vivo and in vitro. Ann N Y Acad Sci 2007;1110:439-447.
28. Vento S, Cainelli F, Mirandola F, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 1996;347:92-93.
29. Streiff MB, Mehta S, Thomas DL. Peripheral blood count abnormalities among patients with hepatitis C in the United States. Hepatology 2002;35:947-952.
30. Giannini E, Borro P, Botta F, et al. Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. J Hepatol 2002;37:572-577.
31. Sansonno D, Lotesoriere C, Cornacchiulo V, et al. Hepatitis C virus infection involves CD34(+) hematopoietic progenitor cells in hepatitis C virus chronic carriers. Blood 1998;92:3328-3337.
32. El Barbary MA, Saad AE, Attia FM, et al. Thrombocytopenia in patients with chronic hepatitis C: a possible role of HCV on platelet progenitor cell maturation. Angiology 2010;61:304-313.
33. López-Medrano F, Fernández-Ruiz M, Morales JM, et al. Impact of hepatitis C virus infection on the risk of infectious complications after kidney transplantation: Data from the RESITRA/REIPI cohort. Transplantation 2011;92:543-549.
34. Reddy S, Sullivan R, Zaiden R, et al. Hepatitis C infection and the risk of bacteremia in hemodialysis patients with tunneled vascular access catheters. South Med J 2009;102:374-377.
35. Ono Y, Watanabe T, Matsumoto K, et al. Opsonophagocytic dysfunction in patients with liver cirrhosis and low responses to tumor necrosis factor-alpha and lipopolysaccharide in patients' blood. J Infect Chemother 2004;10:200-207.
36. Pavio N, Lai MM. The hepatitis C virus persistence: How to evade the immune system? J Biosci 2003;28:287-304.
37. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912-2919.
38. Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med 2011;364:2429-2438.
39. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
40. Peffault de Latour R, Asselah T, Lévy V, et al. Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 2005;36:709-713.
41. Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: One pill a day for tomorrow. Liver Int 2012;32(suppl 1):88-102.